Board of Director Meeting Highlights
King City, Ontario
December 13, 2012

CEO Report
Shelly Jamieson, CEO, referred the Directors to the CEO Report and commented on progress against the 2012/13 Corporate Plan, the development of operational priorities for the upcoming 2013/14 fiscal year, and recruitment of the Vice-President, Finance and Corporate Services role and Senior Scientific Leaders and Expert Leads.

2013/14 Corporate Plan
The 2013/14 Corporate Plan reflecting the Partnership's work plan for the next year to advance the 2012-2017 Strategic Plan was tabled following its review at the November 27, 2012 Performance Committee meeting. The Board approved the 2013/14 Corporate Plan as amended. The Board also reviewed and approved phased approaches for specific program activities, as well as budgets for the Patient Experience and Outcomes Initiative, Survivorship Initiative and Quality Implementation Initiative.

Canadian Partnership for Tomorrow Project (CPTP) update
Dr. Heather Bryant, VP, Cancer Control, reviewed the progress of the Canadian Partnership for Tomorrow Project (CPTP), noting the rapid progress in enrolment though some jurisdictions remain below recruitment targets. Venous blood sample collection to date is below the rate needed to reach the target of 90,000 samples by March 2013.

As articulated in the Partnership's renewal statement from the federal government, the Partnership is investing in enhancements to CPTP to facilitate the study of cardiovascular disease. A Cardiovascular Disease Research Competition was held and the CPTP International Scientific Advisory Board (ISAB) reviewed the applications to identify the successful applicant. The Board gave approval to the CPTP team to execute a contract with the successful applicant, and to work with the Strategic Advisory Council and the ISAB to arrive at final decisions for awarding the funds allocated to this initiative. The Board also passed decisions related to institutional overhead and payment for diagnostic tests beyond the core dataset required by the ISAB.

Performance indicators
The Board discussed the routine reporting of the Partnership's progress and performance, given the new performance measurement strategy. Management will provide a new proposed template to the Board for review prior to using it to report Q1 results in 2013.

Performance/financial items
- The Board approved the 2012/13 Corporate Plan: Risk and Forecast Summary Report as at October 31, 2012.

- The Board approved the interim financial statements for the six months ended September 30, 2012.
- The Board approved the implementation of the accounting standards for not-for-profit organizations for the fiscal year ending March 31, 2013.
- The Board approved the audit of the fiscal year ending March 31, 2012 using the accounting standards for not-for-profit organizations.

Human Capital Committee Terms of Reference
The Board reviewed the purpose and intent of the new Human Capital Board committee and approved the committee's Terms of Reference as presented.

Governance items
- Four Board members' terms (three elected and one appointed) are ending in June 2013 and all four of these members will have completed the maximum term of six years on the Board. Darren Dick, Vice-Chair of the Governance and Nominating Committee, outlined the recruitment process to fill the upcoming vacancies.
- The Board appointed Pamela Fralick, as identified by the Canadian Cancer Society, to the Board of Directors as the Director at large who is affiliated with the Canadian Cancer Society for a term commencing January 2013.
- Mr. Dick updated the Board on the November 21, 2012 meeting of the Governance and Nominating Committee, which was held to review Board composition, term and selection of members, legislative changes, transition, communication, and committees, and to bring forward recommendations and observations to the Board. The Governance and Nominating Committee will circulate a survey for the Board to provide input, and will report back at the April 2013 Board meeting.